Phase 2a Study to Evaluate Suppression of 5-Fluorouracil -Induced Mucositis by TK112690

Trial Title: Phase 2a Study to Evaluate Suppression of 5-Fluorouracil -Induced Mucositis by TK112690

NCT ID: NCT05669521

Condition: Mucositis

Conditions: Official terms:
Mucositis

Conditions: Keywords:
Mucositis
Uridine Phosphorylase Inhibitor
Chemotherapy
5 FU/ LU
Colorectal cancer

Study type: Interventional

Study phase: Phase 2

Overall status: Active, not recruiting

Study design:

Allocation: Randomized

Intervention model: Parallel Assignment

Intervention model description: A total of 24 patients will be enrolled into one of 2 different: TK112690 treated or placebo treated

Primary purpose: Prevention

Masking: Triple (Participant, Care Provider, Investigator)

Masking description: The study will be partially blinded. The patient and investigator as well as site personnel will be blinded as to whether TK-90 or TK-90 placebo is administered. The CRO, sponsor, and site pharmacist will know whether the patient was administered active drug or TK-90 placebo.

Intervention:

Intervention type: Drug
Intervention name: TK-112690
Description: TK112690 treatment Post 5-FU chemotherapy
Arm group label: TK112690

Intervention type: Drug
Intervention name: Placebo
Description: Placebo treatment Post 5-FU chemotherapy
Arm group label: Placebo

Summary: Patients expected to receive a 500 mg/m2 of Leucovorin by iv & 500 mg/m2 of Fluorouracil (5FU) by iv bolus for their Colorectal Cancer. The patients will receive a one-hour infusion of TK-90 or equivalent TK-90 placebo depending on randomization at 5 hours & 11 hours post 5-FU iv bolus. This treatment cycle will continue weekly for 6 weeks. The TK112690 dose will be 45 mg/kg.

Detailed description: Patients expected to receive a 500 mg/m2 of Leucovorin by iv & 500 mg/m2 of Fluorouracil (5FU) by iv bolus for their Colorectal Cancer. The patients will receive a one-hour infusion of TK-90 or equivalent TK-90 placebo depending on randomization at 5 hours & 11 hours post 5-FU iv bolus. This treatment cycle will continue weekly for 6 weeks. The TK112690 dose will be 45 mg/kg. - 24 patients will be randomized equally into 2 different groups: TK-90 treated or TK-90 placebo treated. - Screening must be completed within 2 weeks. - The treatment period for the study is 6 weeks. - Study follow-up will be scheduled post two weeks of completion of last dose of Chemotherapy & TK-90 - Blinding: The study will be partially blinded. The patient and investigator as well as site personnel will be blinded as to whether TK-90 or TK-90 placebo is administered. The CRO, sponsor, and site pharmacist will know whether the patient was administered active drug or TK-90 placebo

Criteria for eligibility:
Criteria:
Inclusion Criteria: 1. Male and female patients 18 to 75 years old (both inclusive) with a histologically or cytological confirmed diagnosis of colorectal cancer 2. Patient scheduled to receive bolus 5 FU along with LV as first line or subsequent therapy for treating locally advanced or residual or recurrent or metastatic colorectal cancer. 3. No prior systemic treatments for cancer (chemotherapy and/or radiotherapy) 4 weeks prior to screening. 4. Be able to read and understand and provide a signature or thumb impression on the Informed Consent Form (ICF) before entering the study. 5. No other concurrent, active, invasive malignancy. 6. ECOG performance status of 0 to 2. 7. Must have a life expectancy of at least 6 months. 8. No active angina or uncontrolled arrhythmia. 9. Not pregnant or nursing. Women of childbearing potential must have a negative serum pregnancy test at screening and on the day before dosing and must use medically acceptable methods of birth control. Acceptable methods of birth control include oral or transdermal contraceptives, condoms, spermicidal foam, IUD, progestin implant or injection, abstinence, vaginal ring, or sterilization of partner. The reason for non-childbearing potential, such as bilateral tubal ligation, bilateral oophorectomy, hysterectomy, or post-menopausal for more than or equal to 1 year, must be specified in the patient's medical history file and CRF. 10. Mucositis Grade less than or equal to 1 per WHO Scale and Xerostomia of Grade less than or equal to 2 per CTCAE 11. Adequate bone marrow function as per CTCAE V5, defined as follows: i) Absolute neutrophil count more than or equal to 1500 cells/mm3 based upon CBC/differential obtained within 2 weeks prior to randomization ii) Platelets more than or equal to 100,000 cells/mm3 based upon CBC/differential obtained within 2 weeks prior to randomization iii) Hemoglobin more than or equal to 8.0 g/dl based upon CBC/differential obtained within 2 weeks prior to randomization (Note: The use of transfusion or other intervention to achieve Hgb more than 8.0 g/dl is acceptable). 12. Adequate hepatic function with bilirubin less than or equal to 1.5 x upper-normal limit (ULN), AST or ALT less than or equal to 3x ULN within 2 weeks prior to randomization 13. Adequate renal function with serum creatinine less than 1.5 mg/dl and creatinine clearance (CrC) more than or equal to 50 ml/min within 2 weeks prior to randomization determined by 24-hour collection or estimated by Cockcroft-Gault formula. CrC male is equal to [(140 - age) x (wt in kg)] / [(Serum Cr mg/dl) x (72)]. CrC female is equal to 0.85 x (CrCl male) 14. Normal serum calcium or normal corrected serum calcium within 2 weeks prior to randomization; formula for corrected calcium if albumin valued is below normal range: Corrected calcium (mg/dl) is equal to (4 - [patients albumin (g/dl)] x 0.8) + patient measured calcium (mg/dl). Exclusion Criteria: 1. An active infection including HIV/ HBV/ HCV infection. 2. Patients who have not fully recovered after prior surgery. (Patients who have had prior surgery and have fully recovered and patients who may have surgery in the future are eligible.) 3. Unstabilized or symptomatic brain metastasis (History of brain metastases allowed if disease has stabilized or improved after radiation and/or craniotomy). 4. Pregnant or nursing mother. 5. Prior history of a cerebrovascular accident or hemorrhage. 6. Congestive heart failure, as defined by New York Heart Association class III or IV. 7. Uncontrolled hypertension. 8. Active psychiatric/mental illness making informed consent or useful clinical follow-up unlikely. 9. Patients who have previously been enrolled into this study and subsequently withdrew. 10. Patient receiving other investigational agent(s). 11. Any systemic immunosuppressive medication/therapy (eg, other chemotherapy, steroids). 12. Any prohibited prior or concomitant therapy 2 weeks prior to enrollment. 13. Presence of any significant systemic illness, unstable or severe medical condition(s) that could put the patient at risk during the study, interfere with outcome measures, or affect compliance with the protocol procedures such as intercurrent infection and/or autoimmune disease, ie, any condition that compromises the immune system. 14. Known or suspected intolerance or hypersensitivity to the study materials (TK 90 and/or excipients or closely related compounds). 15. Patients that have a history of poor compliance in clinical research studies. 16. Patients that have participated in any other investigative clinical trial in the past 4 weeks.

Gender: All

Minimum age: 18 Years

Maximum age: 75 Years

Healthy volunteers: No

Locations:

Facility:
Name: Jawaharlal Nehru Cancer Hospital and Research Centre

Address:
City: Bhopal
Zip: 462001
Country: India

Facility:
Name: Om Sai Onco Surgery Multispecialty Hospital Center

Address:
City: Kolhapur
Zip: 416006
Country: India

Facility:
Name: B. J. Medical College and Sassoon General Hospital

Address:
City: Pune
Zip: 411001
Country: India

Facility:
Name: MTES Sanjeevan Hospital

Address:
City: Pune
Zip: 411001
Country: India

Facility:
Name: Saveetha Medical college Chennai

Address:
City: Chennai
Zip: 602105
Country: India

Start date: June 15, 2022

Completion date: September 2023

Lead sponsor:
Agency: Tosk, Inc.
Agency class: Industry

Collaborator:
Agency: SIRO Clinpharm Pvt. Ltd.
Agency class: Other

Source: Tosk, Inc.

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT05669521